KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Non-Current Debt (2023 - 2025)

Biocryst Pharmaceuticals' Non-Current Debt history spans 8 years, with the latest figure at $194.4 million for Q3 2025.

  • For Q3 2025, Non-Current Debt fell 38.17% year-over-year to $194.4 million; the TTM value through Sep 2025 reached $194.4 million, down 38.17%, while the annual FY2024 figure was $314.9 million, 3.84% up from the prior year.
  • Non-Current Debt reached $194.4 million in Q3 2025 per BCRX's latest filing, down from $242.8 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $315.4 million in Q1 2025 to a low of $194.4 million in Q3 2025.
  • Average Non-Current Debt over 3 years is $284.6 million, with a median of $303.2 million recorded in 2023.
  • Peak YoY movement for Non-Current Debt: surged 32.67% in 2024, then tumbled 38.17% in 2025.
  • A 3-year view of Non-Current Debt shows it stood at $303.2 million in 2023, then rose by 3.84% to $314.9 million in 2024, then tumbled by 38.27% to $194.4 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Non-Current Debt are $194.4 million (Q3 2025), $242.8 million (Q2 2025), and $315.4 million (Q1 2025).